This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Opioids Market To 2018 - Increasing Concentration Of Abuse-Resistant Branded Generics Alter Competitive Dynamics In This Flat Market

NEW YORK, Jan. 14, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Opioids Market to 2018 - Increasing Concentration of Abuse-Resistant Branded Generics Alter Competitive Dynamics in this Flat Market

http://www.reportlinker.com/p01081138/Opioids-Market-to-2018---Increasing-Concentration-of-Abuse-Resistant-Branded-Generics-Alter-Competitive-Dynamics-in-this-Flat-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Opioids Market to 2018 - Increasing Concentration of Abuse-Resistant Branded Generics Alter Competitive Dynamics in this Flat Market

Summary

Leading business intelligence provider GBI Research has released its latest research report, entitled "Opioids Market to 2018 - Increasing Concentration of Abuse-Resistant Branded Generics Alter Competitive Dynamics in this Flat Market". The current opioids market is characterized by a very broad and highly diversified product portfolio. Patients experiencing moderate to severe pain for a range of underlying physiological reasons are virtually exclusively treated with opioid analgesics. As a result, most patient populations experiencing more severe levels of pain across most pain indications, with the exception of, for example, migraines, are heavily dominated by opioids. As a therapeutic drug class, opioids have virtually no competition from molecules with non-opioid receptor targets. However, although the competition is virtually exclusively limited to opioid compounds, the current environment within this therapeutic class is highly competitive and strongly diversified. The approved drugs are based on 16 different opioid compounds and are differentiated on a range of characteristics, which include dosage, route of administration and pharmacokinetic features, as well as increasingly on the basis of abuse-resistance technologies.

Whilst the prescription rates of opioid analgesic have seen a historically unprecedented increase over the last two decades, particularly in the US, this has resulted in a dramatic concomitant increase in opioid abuse and dependency. Over the last few years, the growing concern over opioid abuse has resulted in tighter regulations and increasingly vocal concerns by physicians. Due to these concerns from regulatory authorities and physicians about growing opioid abuse, there has been a seismic shift towards developing abuse-resistant formulations of extended-release opioid analgesics, including both novel products and reformulations of existing ones. Since the launch of the first abuse-resistant product, Embeda, in 2009, a whole range of novel products and reformulations of existing product ranges have been brought to the market. While abuse-resistant formulations do not confer any clinical benefits, they have become an essential differentiating factor in the current market environment in order ensure that products remain competitive for the future. There is a growing concentration and competition among abuse-resistant products, which is expected to be the primary driving factor in this largely stagnant market, particularly as the current developmental pipeline is very small and is characterized by a lack of innovation, with virtually no novel compounds and strong saturation across multiple pain indications.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,131.84 -242.92 -1.48%
S&P 500 1,925.30 -25.83 -1.32%
NASDAQ 4,693.3540 -40.1430 -0.85%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs